Serotype Distribution and Antimicrobial Resistance of *Shigella* Species in Bangui, Central African Republic, from 2002 to 2013

Sebastien Breurec,^{1,2,3*} Clotaire Rafai,¹ Manuella Onambele,¹ Thierry Frank,¹ Alain Farra,¹ Arnaud Legrand,⁴ and François-Xavier Weill^{5*}

¹Laboratoire de Bactériologie, Institut Pasteur de Bangui, Bangui, Central African Republic; ²Faculté de Médecine Hyacinthe Bastaraud, Université des Antilles, Pointe-à-Pitre, France; ³Laboratoire de Microbiologie Clinique et Environnementale, Centre Hospitalier Universitaire de Pointe-à-Pitre/les Abymes, Pointe-à-Pitre, France; ⁴Délégation à la Recherche Clinique et à l'Innovation, Centre Hospitalier Universitaire de Nantes, Nantes, France; ⁵Unité des Bactéries Pathogènes Entériques, Centre National de Référence des *Escherichia coli*, *Shigella* et *Salmonella*, Institut Pasteur, Paris, France

Abstract. *Shigella* is a major cause of severe diarrhea in children less than the age of 5 years in sub-Saharan Africa. The aim of this study was to describe the (sub-)serotype distribution and antimicrobial susceptibility of *Shigella* serogroups from Centrafrican patients with diarrhea between 2002 and 2013. We collected 443 *Shigella* isolates in total. The most common serogroups were *Shigella flexneri* ($N = 243$, 54.9%), followed by *Shigella sonnei* ($N = 90$, 20.3%) and *Shigella dysenteriae* ($N = 72$, 16.3%). The high diversity of (sub-)serotypes of *S. flexneri* and *S. dysenteriae* may impede the development of an efficient vaccine. Rates of resistance were high for ampicillin, chloramphenicol, tetracycline, and cotrimoxazole but low for many other antimicrobials, confirming recommendations for the use of third-generation cephalosporins (only one organism resistant) and fluoroquinolones (no resistance). However, the detection of one extended-spectrum beta-lactamase-producing *Shigella* organism highlights the need for continued monitoring of antimicrobial drug susceptibility.

INTRODUCTION

In 2013, 6.3 million deaths were recorded in children less than the age of 5 years, 578,000 of which were because of diarrheal disease, the second leading cause of death in this age group. Almost half of these diarrhea-related deaths occurred in sub-Saharan Africa.¹ Recent studies (Torcadia for Central African Republic [CAR] and the Global Enteric Multi-center Study for other sites) in The Gambia and Mali (West Africa), Mozambique and Kenya (East Africa), and CAR (Central Africa) have confirmed the continuing importance of *Shigella* as a major cause of severe diarrhea in children less than the age of 5 years. *Shigella* spp. are the third most important pathogen in these regions.^{2,3}

High rates of resistance to conventional antimicrobials, such as ampicillin, chloramphenicol, tetracycline, and cotrimoxazole, have been reported for *Shigella* spp. in many studies.⁴ This resistance has led to third-generation cephalosporins (C3G), fluoroquinolones, and azithromycin becoming the first-line antimicrobials for treating these infections. However, the clinical severity of shigellosis and the emergence of resistance to first-line treatments highlight the growing need to develop alternative prophylactic and therapeutic strategies. The development of a safe and effective anti-*Shigella* vaccine for controlling shigellosis is enshrined in WHO public health policy. However, the presence of four different serogroups (formerly known as species), *Shigella flexneri*, *Shigella dysenteriae*, *Shigella boydii*, and *Shigella sonnei*, made up of at least 50 antigenically different (sub-)serotypes may impede vaccine development.⁵ Indeed, the larger the number of serotypes to be included, the more

complex and expensive the vaccine becomes. The lack of data from Central Africa and from very low-income countries, such as CAR,⁶ which suffers from long-term instability, highlights the need to improve our understanding of the spatial and temporal distribution of (sub-)serotypes in sub-Saharan Africa.^{7,8} Central African Republic is a resource-limited country in equatorial Africa (ranked 180/187 according to the Human Development Index in 2013). Here, we describe the (sub-)serotype distribution and antimicrobial susceptibility of *Shigella* species isolated from patients in CAR during the 2002–2013 period.

Clinical isolates of *Shigella* were obtained between January 2002 and December 2013, from Centrafrican outpatients with diarrhea attending the Institut Pasteur in Bangui. If more than one isolate of the same (sub-)serotype and serogroup and with the same antimicrobial drug resistance phenotype was recovered from a given patient, only the first isolate was included. *Shigella* was identified by conventional methods and (sub-)serotyping was performed by slide agglutination assays with a complete set of antisera recognizing all the described *Shigella* serotypes.⁹ Antimicrobial drug susceptibility was assessed by the disk diffusion method, and extended-spectrum beta-lactamase (ESBL) production was evaluated in the double-disc synergy test, as previously described.¹⁰

Date, site of isolation, patient age, and gender were recorded for each isolate. We used χ^2 test, Student's *t*-test, and ANOVA (analysis of variance—with Lilliefors' test for normality and Levene's test for homoscedasticity) to compare categorical and continuous variables in univariate analysis. Multivariate logistic regression was performed to explore high rates of multidrug resistance (MDR, defined by resistance to more than five of the 13 antimicrobials tested). Factors with *P* values < 0.2 in univariate analysis were retained for the multivariate analysis. We considered *P* values < 0.05 to be statistically significant.

In total, 443 clinical isolates of *Shigella* were collected between January 2002 and December 2013, from 443 Centrafrican outpatients with diarrhea (238 male and 205 female patients, mean age: 27.2 years, median age: 29.5 years, 25th percentile: 8 years, 75th percentile: 40 years). The small number of organisms isolated during the study period reflects

* Address correspondence to Sebastien Breurec, Centre Hospitalier Universitaire de Pointe-à-Pitre/les Abymes, Laboratoire de Microbiologie Clinique et Environnementale, Route de Chauvel, Pointe-à-Pitre, France, E-mail: sebastien.breurec@chu-guadeloupe.fr or François-Xavier Weill, Centre National de Référence des *Escherichia coli*, *Shigella* et *Salmonella*, Unité des Bactéries Pathogènes Entériques, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France, E-mail: francois-xavier.weill@pasteur.fr.

TABLE 1
Distribution of the most frequent *Shigella* serogroups and (sub-)serotypes in Bangui, Central African Republic, 2002–2013

<i>Shigella</i>	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	Total	
Serogroups/serotypes	<i>n</i> (%)	<i>n</i> (%)	<i>N</i> = 59 <i>n</i> (%)	<i>N</i> = 60 <i>n</i> (%)	<i>N</i> = 82 <i>n</i> (%)	<i>N</i> = 51 <i>n</i> (%)	<i>N</i> = 26 <i>n</i> (%)	<i>N</i> = 11 <i>n</i> (%)	<i>N</i> = 8 <i>n</i> (%)	<i>N</i> = 39 <i>n</i> (%)	<i>N</i> = 44 <i>n</i> (%)	<i>N</i> = 27 <i>n</i> (%)	<i>N</i> = 443 <i>n</i> (%)	<i>P</i>
<i>flexneri</i> *														
1	8 (57.1)	14 (63.6)	34 (57.6)	34 (56.7)	49 (59.8)	32 (62.7)	9 (34.6)	5 (45.4)	5 (62.5)	18 (46.2)	22 (50.0)	13 (48.1)	243 (54.9)	NS
1a	0	0	0	0	1 (1.2)	0	0	0	0	0	0	0	1 (0.2)	NS
1b	0	5 (22.7)	11 (18.7)	13 (21.7)	15 (18.3)	5 (9.8)	3 (11.5)	0	1 (12.5)	0	1 (2.3)	0	3 (0.7)	0.03
1c	1 (7.1)	0	6 (10.2)	0	0	2 (3.9)	0	0	2 (25.0)	2 (5.1)	2 (4.5)	1 (3.7)	59 (13.3)	0.03
2a	7 (50.0)	5 (22.7)	3 (5.1)	8 (13.3)	3 (3.7)	6 (11.8)	0	1 (9.1)	0	1 (2.6)	6 (13.6)	0	9 (2.0)	0.002
3a	0	0	7 (11.9)	2 (3.3)	7 (8.5)	8 (15.7)	3 (11.5)	1 (9.1)	1 (12.5)	2 (5.1)	3 (6.8)	4 (14.8)	40 (9.0)	<0.001
3b	0	0	0	0	1 (1.2)	0	0	0	0	0	1 (2.3)	0	2 (0.5)	NS
4a	0	1 (4.5)	0	0	3 (3.7)	7 (13.7)	2 (7.7)	1 (9.1)	0	2 (5.1)	5 (11.4)	4 (14.8)	25 (5.6)	0.02
4c	0	0	2 (3.4)	4 (6.7)	2 (2.4)	1 (2.0)	0	0	0	1 (2.6)	0	0	10 (2.3)	NS
6 ^a	0	3 (13.6)	5 (8.5)	7 (11.7)	15 (18.3)	3 (5.9)	1 (3.8)	2 (18.2)	1 (12.5)	10 (25.6)	4 (9.1)	3 (11.1)	64 (14.4)	NS
7	0	0	0	0	0	0	0	0	0	0	0	1 (3.7)	1 (0.2)	NS
8	0	0	0	0	0	0	1 (3.8)	0	1 (12.5)	0	0	0	1 (0.2)	NS
9	0	0	0	0	0	0	0	0	0	0	0	0	1 (0.2)	NS
Y	0	0	0	0	1 (1.2)	0	0	0	0	0	0	0	1 (0.2)	NS
Prov93-119	0	0	0	0	0	0	0	0	0	0	0	1 (3.7)	1 (0.2)	NS
Prov96-204	0	0	0	0	0	0	0	0	0	0	0	1 (3.7)	1 (0.2)	NS
<i>sonnei</i>	4 (28.6)	1 (4.5)	7 (11.9)	9 (15.0)	9 (11.0)	8 (15.7)	9 (34.6)	4 (36.4)	1 (12.5)	18 (46.2)	13 (29.5)	7 (25.9)	90 (20.3)	<0.001
dysenteriae†	0	5 (22.7)	11 (18.6)	12 (20)	15 (18.3)	6 (11.8)	6 (23.1)	0	1 (12.5)	3 (7.7)	6 (13.6)	7 (25.9)	72 (16.3)	NS
2	0	3 (13.6)	8 (13.6)	7 (11.7)	9 (11.0)	3 (5.9)	1 (3.8)	0	0	0	2 (4.5)	0	33 (7.4)	NS
3	0	2 (9.1)	0	5 (8.3)	5 (6.1)	1 (2.0)	1 (3.8)	0	0	2 (5.1)	3 (6.8)	0	19 (4.3)	NS
4	0	0	0	0	1 (1.2)	2 (3.9)	1 (3.8)	0	0	0	0	2 (7.4)	6 (1.3)	NS
12	0	0	0	0	0	0	2 (7.7)	0	0	1 (2.6)	0	3 (11.1)	6 (1.3)	0.03
<i>boydii</i>	2 (14.3)	2 (9.1)	7 (11.9)	4 (6.7)	9 (11.0)	4 (7.8)	2 (7.7)	2 (18.2)	0	0	2 (4.5)	0	34 (7.7)	NS
1	1 (7.1)	1 (4.5)	2 (3.4)	1 (1.7)	2 (2.4)	0	0	0	0	0	1 (2.3)	0	8 (1.8)	NS
2	0	0	0	2 (3.3)	4 (4.9)	0	1 (3.8)	1 (9.1)	0	0	0	0	8 (1.8)	NS
4	0	0	3 (5.1)	1 (1.7)	0	1 (2.0)	0	1 (9.1)	0	0	0	0	6 (1.3)	NS
18	1 (7.1)	0	1 (1.7)	0	1 (1.2)	0	1 (3.8)	0	0	0	0	0	4 (0.9)	NS
Undetermined	0 (0)	0 (0)	0 (0)	1 (1.7)	0 (0)	1 (2.0)	0 (0)	0 (0)	1 (12.5)	0 (0)	1 (2.3)	0 (0)	4 (0.9)	NS

* *Shigella flexneri* serotypes proposed for inclusion, along with *S. sonnei*, in a quadrivalent broad-spectrum *Shigella* vaccine are shown in bold.

† Only the four most frequent serotypes are shown.

TABLE 2
Percentage resistance to specific antibiotics in *Shigella* species in Bangui, Central African Republic, from 2002 to 2013

	<i>Shigella flexneri</i> (%) N = 243	<i>Shigella sonnei</i> (%) N = 90	<i>Shigella dysenteriae</i> (%) N = 72	<i>Shigella boydii</i> (%) N = 34	Unknown (%) N = 4	Total (%) N = 443
Amoxicillin	72	19	85	68	100	64
Co-amoxiclav	6	2	1	3	0	4
Ticarcillin	71	19	85	65	100	61
Cefoxitin	0	0	0	0	0	0
Cefotaxime	0	0	0	0	0	0
Amikacin	0	0	0	0	0	0
Gentamicin	0	0	0	0	0	0
Nalidixic acid	0	0	1	0	0	0
Ciprofloxacin	0	0	0	0	0	0
Chloramphenicol	74	20	85	32	75	62
Sulfonamides	92	98	96	91	100	94
Cotrimoxazole	90	97	94	88	100	92
Tetracycline	98	99	99	97	100	98

the poor access to health-care services in CAR, particularly for the laboratory diagnosis of diarrhea. Significant differences in the number of isolates obtained were also observed between years because of the economic and political crisis that occurred during the study period, further restricting patient access to health-care facilities. However, the distribution of serogroups recovered in our study for 2004–2005 was consistent with that reported for the same period in a study conducted at four health-care centers in Bangui.⁶ The data reported here may, therefore, be considered representative of the global situation in Bangui.

The incidence of *S. dysenteriae* infection has been reported to be higher in men than in women in China.¹¹ By contrast, we found a significant association between *S. dysenteriae* infection and being female (odds ratio = 1.86 95% confidence interval [1.11–3.12]; $P = 0.018$). No significant association was found between gender and the other serogroups or between *Shigella* serogroup and age. Contrary to several other reports,^{11,12} we observed no significant seasonality in the distribution of *Shigella* isolates or in serogroup distribution (i.e., erratic variation between months, but no difference between the wet and dry seasons).

The most common serogroup was *S. flexneri* ($N = 243$, 54.9%), consistent with several reports from developing countries in Africa and Asia,^{5,13} followed by *S. sonnei* ($N = 90$, 20.3%) and *S. dysenteriae* ($N = 72$, 16.3%). *Shigella boydii* ($N = 34$, 7.7%), which is generally restricted to North and East Africa (Ethiopia and Egypt) and South Asia (Bangladesh and Nepal),¹³ was rarely encountered in our study (Table 1). Unsurprisingly, no significant difference in the prevalence of *Shigella* serogroups was observed during the study period,

except for *S. sonnei* ($P < 0.001$). However, the prevalence of the *S. sonnei* serogroup fluctuated over time, with no significant trend (Table 1). This finding is consistent with the known distribution of *Shigella* serogroups in countries with a low socioeconomic level,⁴ CAR being one of the poorest countries of sub-Saharan Africa.

An increase in the frequency of *S. sonnei* isolates relative to *S. flexneri* has been reported worldwide, in regions in which sanitation and clean water provision have been improved.¹⁴ Such interactions between these two serogroups were detected here, by analyzing the negative correlation between proportions and incidence, which was strong year after year ($r = -0.8164$; $P = 0.001$), whereas an erratic pattern was observed between years (Table 1). Five serotypes/subserotypes of *S. flexneri* accounted for 50.9% of all isolates: 6 (14.4% of the total), 1b (13.3%), 2a (9.0%), 3a (8.6%), and 4a (5.6%). Only minimal changes in serotype distribution were observed from year to year, for most of the (sub-)serotypes, and any significant variation detected was inconsistent (Table 1). *Shigella dysenteriae* serotype 1, which is a source of great concern as it has caused devastating epidemics of shigellosis in various developing countries, including CAR,¹⁵ was recovered only rarely in our laboratory (one organism in 2006).

No significant cross-reactions are known between serotypes in *S. dysenteriae* (15 serotypes) and *S. boydii* (20 serotypes), but major cross-reactions were observed for 14 of the 19 serotypes of *S. flexneri*, because of a degree of antigenic relatedness attributable to a common repeating tetrasaccharide unit.¹⁶ Thus, a multivalent vaccine including O antigens from *S. flexneri* 2a and 3a, in addition to direct protection against *S. flexneri* 2b and 3b, would provide cross-protection

TABLE 3
Determinants of the high rates of multidrug resistance (defined by resistance to more than five of the 13 antibiotics tested) in *Shigella* spp. strains from Bangui, Central African Republic, 2002–2013

	Rate of multidrug resistance % (n)		Univariate analysis		Multivariate analysis	
	Yes (N = 216)	No (N = 227)	OR (95% CI)	P	Adjusted OR (95% CI)	P
Male	48.6 (105)	57.7 (131)	0.72 (0.49–1.05)	0.086	0.76 (0.50–1.14)	0.189
Q4 age*	21.8 (47)	23.3 (53)	0.91 (0.58–1.43)	0.689	—	—
<i>flexneri</i> †	62.5 (135)	47.6 (108)	1.84 (1.26–2.69)	0.002	0.41 (0.04–3.85)	0.436
<i>sonnei</i> †	6.9 (15)	33.0 (75)	0.15 (0.08–0.27)	< 0.0001	0.07 (0.01–0.66)	0.019
<i>dysenteriae</i> †	25.6 (55)	7.5 (17)	4.22 (2.36–7.56)	< 0.0001	1.03 (0.10–10.05)	0.978
<i>boydii</i> †	3.7 (8)	11.5 (26)	0.30 (0.13–0.67)	0.003	0.10 (0.01–1.10)	0.059
Undefined†	1.4 (3)	0.5 (1)	3.18 (0.33–31.03)	0.317	—	—

* Q4 age-defined extreme population quartile.

† Serogroup.

against *S. flexneri* 1a, 1b, 4a, 4b, 5a, 5b, 7b, X, and Y.^{17,18} Extrapolating these data to humans, a multivalent vaccine including *S. sonnei* (only one serotype described) and *S. flexneri* 2a, 3a, and 6 would have provided direct protection for 52.3% and cross-protection for 72.9% of these infections. This level is lower than that estimated for two multicenter studies at four sites in Africa and nine sites at Asia,^{5,19} in which a quadrivalent vaccine including the serotypes listed previously would have provided protection against at least 85% of the serotyped organisms. However, these cross-reactions remain theoretical and discrepancies exist between data for humans and animals, as highlighted by the appearance of cross-reactive type six antibodies in humans, but not in mice, after vaccination with *S. flexneri* 2a conjugate.²⁰ Together with the considerable diversity of (sub-)serotypes in two of the three major serogroups (*S. flexneri* and *S. dysenteriae*) recovered in our study, this constitutes a real barrier to the development of a cheap, safe vaccine providing broad coverage against *Shigella*.

The ability of *Shigella* to acquire antimicrobial drug resistance rapidly is a major challenge in the control of infections with this bacterium. Overall, resistance rates to antimicrobials were low during the study period, for all classes other than conventional antimicrobials (chloramphenicol [62%], amoxicillin [64%], cotrimoxazole [92%], and tetracycline [98%]), confirming recommendations for first-line treatment based on C3G and fluoroquinolones (Table 2). However, although no resistance to ciprofloxacin was detected, we report the first case of ESBL-producing *Shigella* (*S. flexneri*) in sub-Saharan Africa, which is of major concern. Unlike *S. sonnei*, the *S. flexneri*, *S. dysenteriae*, and *S. boydii* serotypes were all strongly associated with high rates of MDR (Table 2). After adjustment for gender and serogroup, multivariate analysis highlighted a significant contribution of the antimicrobial drug resistance pattern of *S. sonnei* to the rates of MDR of *Shigella* isolates (OR = 0.02 95% CI [0.007–0.65]; $P < 0.001$), despite the lower prevalence of *S. sonnei* than that of *S. flexneri* (Table 3).

The data reported here are particularly important, given the difficulty of carrying out such studies in countries with inadequate health-care systems. The high diversity of *S. flexneri* and *S. dysenteriae* (sub-)serotypes observed here may act as a major obstacle to the development of a vaccine. Resistance to front-line antimicrobials is low, but it will be important to continue monitoring antimicrobial drug susceptibility in *Shigella* isolates.

Received November 23, 2017. Accepted for publication April 11, 2018.

Published online June 25, 2018.

Acknowledgments: We thank Isabelle Carle, Monique Lejay-Collin, Malika Gouali, and Corinne Ruckly for excellent technical assistance.

Financial support: The French National Reference Center for *Escherichia coli*, *Shigella*, and *Salmonella* is funded by the Institut Pasteur and Santé Publique France. The Unité des Bactéries Pathogènes Entériques belongs to the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence funded by the French Government as part of the Investissement d'Avenir program (grant no. ANR-10-LABX-62-IBEID).

Authors' addresses: Sebastien Breurec, Faculté de Médecine, Université des Antilles, Pointe-à-Pitre, France, E-mail: sbreurec@gmail.com. Clotaire Rafai, Manuella Onambele, Thierry Frank, and Alain Farra, Laboratoire de Bactériologie, Institut Pasteur de Bangui, Bangui, République Centrafricaine, E-mails: clotaire-rafaï@yahoo.fr, onambelemanu@yahoo.fr, thierryfrank@yahoo.fr, and farra_alain@yahoo.fr. Arnaud Legrand, DRCI, Centre Hospitalier Universitaire de Nantes, Nantes, France, E-mail: arnaud.legrand@chu-nantes.fr.

François-Xavier Weill, Unité des Bactéries Pathogènes Entériques, Centre National de Référence des *Escherichia coli*, *Shigella* et *Salmonella*, Institut Pasteur, Paris, France, E-mail: fxweill@pasteur.fr.

REFERENCES

1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE, 2015. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. *Lancet* 385: 430–440.
2. Kotloff KL et al., 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet* 382: 209–222.
3. Breurec S et al., 2016. Etiology and epidemiology of diarrhea in hospitalized children from low income country: a matched case-control study in Central African Republic. *PLoS Negl Trop Dis* 10: e0004283.
4. Anderson M, Sansonetti PJ, Marteyn BS, 2016. *Shigella* diversity and changing landscape: insights for the twenty-first century. *Front Cell Infect Microbiol* 6: 45.
5. Livio S et al., 2014. *Shigella* isolates from the global enteric multicenter study inform vaccine development. *Clin Infect Dis* 59: 933–941.
6. Bercion R, Njuimo SP, Boudjeka PM, Manirakiza A, 2008. Distribution and antibiotic susceptibility of *Shigella* isolates in Bangui, Central African Republic. *Trop Med Int Health* 13: 468–471.
7. Qiu S et al., 2015. Shift in serotype distribution of *Shigella* species in China, 2003–2013. *Clin Microbiol Infect* 21: 252 e5–8.
8. Bangtrakulnonth A, Vieira AR, Lo Fo Wong DM, Pornreongwong S, Pulsrikam C, Sawanpanyale P, Hendriksen RS, Aarestrup FM, 2008. *Shigella* from humans in Thailand during 1993 to 2006: spatial-time trends in species and serotype distribution. *Foodborne Pathog Dis* 5: 773–784.
9. Langendorf C, Le Hello S, Moumouni A, Gouali M, Mamaty AA, Grais RF, Weill FX, Page AL, 2015. Enteric bacterial pathogens in children with diarrhea in Niger: diversity and antimicrobial resistance. *PLoS One* 10: e0120275.
10. Rafai C, Frank T, Manirakiza A, Gaudeuille A, Mbecko JR, Nghario L, Serdouma E, Tekpa B, Garin B, Breurec S, 2015. Dissemination of IncF-type plasmids in multiresistant CTX-M-15-producing *Enterobacteriaceae* isolates from surgical-site infections in Bangui, Central African Republic. *BMC Microbiol* 15: 15.
11. Mao Y et al., 2013. Changing trends and serotype distribution of *Shigella* species in Beijing from 1994 to 2010. *Gut Pathog* 5: 21.
12. Shakya G, Acharya J, Adhikari S, Rijal N, 2016. Shigellosis in Nepal: 13 years review of nationwide surveillance. *J Health Popul Nutr* 35: 36.
13. Kahsay AG, Muthupandian S, 2016. A review on serodiversity and antimicrobial resistance patterns of *Shigella* species in Africa, Asia and South America, 2001–2014. *BMC Res Notes* 9: 422.
14. Thompson CN, Duy PT, Baker S, 2015. The rising dominance of *Shigella sonnei*: an intercontinental shift in the etiology of bacillary dysentery. *PLoS Negl Trop Dis* 9: e0003708.
15. Bercion R, Demartin M, Recio C, Massamba PM, Frank T, Escriba JM, Grimont F, Grimont PA, Weill FX, 2006. Molecular epidemiology of multidrug-resistant *Shigella dysenteriae* type 1 causing dysentery outbreaks in Central African Republic, 2003–2004. *Trans R Soc Trop Med Hyg* 100: 1151–1158.
16. Levine MM, 2006. Enteric infections and the vaccines to counter them: future directions. *Vaccine* 24: 3865–3873.
17. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB, 2007. Clinical trials of *Shigella* vaccines: two steps forward and one step back on a long, hard road. *Nat Rev Microbiol* 5: 540–553.
18. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM, 1999. Strategy for cross-protection among *Shigella flexneri* serotypes. *Infect Immun* 67: 782–788.
19. von Seidlein L et al., 2006. A multicentre study of *Shigella* diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. *PLoS Med* 3: e353.
20. Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, KubinKielb J, Vinogradov E, Robbins JB, Schneerson R, 2017. Vaccination with *Shigella flexneri* 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice. *Vaccine* 35: 4990–4996.